8 recruiting, 3 active not recruiting, 1 enrolling by invitation. 12 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 8, Active not recruiting 3, Enrolling by invitation 1 |
| Phase 2 | 6 | Recruiting 5, Active not recruiting 1 |
Follow Primary Mediastinal Large B-cell Lymphoma (PMBCL): new trials by email Literature Review of Primary Mediastinal Large B-cell Lymphoma (PMBCL) trials Research Report on Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma 7×19-THEMIS CAR-T cells - Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 70 | 2026-09-01 | 2026-08-26 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies CLIC-2201 - B-Cell Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | British Columbia Cancer Agency | 24 | 2025-01-02 | 2026-10-14 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide - B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Enrolling by invitation | University of Maryland, Baltimore | 15 | 2024-10-28 | 2026-09-14 |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine - Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 24 | 2023-10-26 | 2026-10-09 |
| Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients TC011 - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | TICAROS Co., Ltd. | 98 | 2023-08-03 | 2026-03-16 |
| Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma CD30.CAR-T - Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma | Phase 1 | Active not recruiting | Tessa Therapeutics | 21 | 2021-09-08 | 2023-04-20 |
| Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients CRC01, Fludarabine, Cyclophosphamide - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Curocell Inc. | 91 | 2021-03-02 | 2026-07-01 |
| CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells - Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL) | Phase 1 / Phase 2 | Recruiting | Medical College of Wisconsin | 100 | 2020-05-18 | 2026-02-23 |
| First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma Epcoritamab - DLBCL, High-grade B-cell Lymphoma (HGBCL) | Phase 1 / Phase 2 | Active not recruiting | Genmab | 666 | 2018-06-26 | 2026-11-04 |
Lymphoma, Large B-Cell, Diffuse (11) · Lymphoma, Mantle-Cell (7) · Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Follicular (5) · Lymphoma, Non-Hodgkin (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell (4) · Burkitt Lymphoma (2) · Dendritic Cell Sarcoma, Interdigitating (2) · Recurrence (2) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Biphenotypic, Acute (1) · Lymphoma (1) · Lymphoma, Extranodal NK-T-Cell (1)
Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Lymphoma (11) · Lymphoma, B-Cell (8) · Lymphoma, Non-Hodgkin (7) · Hematologic Diseases (6) · Disease Attributes (5) · Leukemia, Lymphoid (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5)
Cyclophosphamide (3) · fludarabine (3) · fludarabine phosphate (1)
British Columbia Cancer Agency (1) · Curocell Inc. (1) · Genmab (1) · Marcela V. Maus, M.D.,Ph.D. (1) · Medical College of Wisconsin (1) · Poseida Therapeutics, Inc. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · TICAROS Co., Ltd. (1) · Tessa Therapeutics (1) · University of Maryland, Baltimore (1) · Verismo Therapeutics (1) · Vironexis Biotherapeutics Inc. (1)
United States (8) · South Korea (3) · Canada (2) · Australia (1) · China (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Singapore (1) · Spain (1) · Sweden (1)
Djordje Atanackovic, MD (1) · Kevin Hay, MD (1) · Laura A Johnson, PhD (1) · Matthew Frigault, MD (1) · Nirav Shah, MD (1) · Sairah Ahmed (1) · Simon Heidegger, MD (1) · Wenbin Qian,Professor (1)
PMID 34508654, PMID 34515338, PMID 34628052, PMID 35597752, PMID 36548927, PMID 38151388, PMID 38889737, PMID 39322711, PMID 40163793, PMID 40472301, PMID 42212152, PMID 42284198, PMID 42411504, PMID 42431612, PMID 42541678
2017 (1), 2023 (1)